Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

Idiopathic Membranous Nephropathy Treatment Market is projected to witness substantial growth over the next few years, driven ...

The basis for the prevention of diabetic nephropathy is the treatment of its known risk factors: hypertension, hyperglycemia, smoking, and dyslipidemia. These are also risk factors for ...

Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD), and the proportion of patients with ESRD who have diabetes (most of whom have T2DM) has increased over the past ...

The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024 Beijing Time ( 8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be ...

Grappling between fighting through a constant struggle of enduring treatment or entering hospice; preparing to say goodbye – ...

Breakthrough status for nephropathy drug lifts Omeros The FDA has given breakthrough therapy designation to OMS721, a new treatment for the rare kidney disease immunoglobulin A (IgA) nephropathy.

Credit: Thinkstock Investigators attending ASN’s Kidney Week 2024 reported progress on a number of IgA nephropathy drug trials. IgA nephropathy trials of new and emerging therapies that target B ...

IgA nephropathy is the most common primary glomerulonephritis and contributes to kidney failure. Growing evidence exists that ...

The following is a summary of “Association between different proportions of crescents and the progression of IgA nephropathy ...